Clinical Edge Journal Scan

Strong link between polycyclic aromatic hydrocarbons and raised rheumatoid arthritis risk


 

Key clinical point: Exposure to environmental polycyclic aromatic hydrocarbons (PAH) was significantly associated with an increased prevalence of rheumatoid arthritis (RA) in the US population, and PAH mediated the majority of the effects of smoking in RA.

Major finding: Risk of developing RA was significantly higher in participants in the highest vs lowest quartile of 1-hydroxynaphthalene level (adjusted odds ratio [aOR] 1.8; P = .020) and PAH body burden scores (aOR 2.2; P = .028). PAH body burden accounted for ~90% of the total effect of smoking on RA.

Study details: Findings are from a cross-sectional study including adult participants with (n = 1418) or without (n = 20,569) RA who underwent assessments for PAH, phthalate and plasticizer metabolite, and volatile organic compound body burden.

Disclosures: This study did not declare any specific funding source. The lead author declared receiving personal fees from Cleveland HeartLab, unrelated to this study, and holding a patent.

Source: Beidelschies M et al. Polycyclic aromatic hydrocarbons and risk of rheumatoid arthritis: A cross-sectional analysis of the National Health and Nutrition Examination Survey, 2007–2016. BMJ Open. 2023;13(5):e071514 (May 9). Doi: 10.1136/bmjopen-2022-071514

Recommended Reading

Meta-analysis reveals superior efficacy and safety outcomes with abatacept in RA
MDedge Rheumatology
RA raises risk for bronchial asthma and asthma-related comorbidities
MDedge Rheumatology
Mortality risk accrues with time after diagnosis of RA
MDedge Rheumatology
RA causally associated with ischemic heart disease and myocardial infarction
MDedge Rheumatology
Looking at diseases associated with RA, May 2023
MDedge Rheumatology
Researchers seek to understand post-COVID autoimmune disease risk
MDedge Rheumatology
FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
MDedge Rheumatology
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
MDedge Rheumatology
Rheumatoid arthritis linked to increased Parkinson’s risk
MDedge Rheumatology
Investigational drug peresolimab shows efficacy in patients with RA
MDedge Rheumatology